Similarly, BRCA1, BRCA2, and PARP1 tiling sgRNA libraries were used for specific base editing to unravel mutations leading to resistance to a group of PARP inhibitors or to the chemotherapeutic drug cisplatin in various tumor cell lines using next-generation BE3 or BE4 CBEs [110]. Here, PARP1 is linked to neoplasm.